Fatty Acid Hydroxylase-Associated Neurodegeneration
Summary
Clinical characteristics.
Fatty acid hydroxylase-associated neurodegeneration (FAHN) is characterized early in the disease course by central nervous system involvement including corticospinal tract involvement (spasticity), mixed movement disorder (ataxia/dystonia), and eye findings (optic atrophy, oculomotor abnormalities), and later in the disease course by progressive intellectual impairment and seizures. With disease progression, dystonia and spasticity compromise the ability to ambulate, leading to wheelchair dependence. Life expectancy is variable. FAHN is considered to be a subtype of neurodegeneration with brain iron accumulation (NBIA).
Diagnosis/testing.
The diagnosis of FAHN is established in a proband with suggestive findings and typically by identification of biallelic FA2H pathogenic variants on molecular genetic testing; however, on occasion uniparental disomy (UDP) is causative.
Management.
Treatment of manifestations: Symptomatic treatment focuses primarily on the dystonia, which can be debilitating. Therapies used with varying success include the oral medications baclofen, tizanidine, dantrolene, and anticholinergics; injection of botulinum toxin targeting abnormal co-contraction of selected muscle groups; and ablative pallidotomy or thalamotomy. Attention should be given to nutritional status and feeding.
Independence should be encouraged when possible through use of adaptive aids (e.g., walker or wheelchair for gait abnormalities, augmentative communication devices) and appropriate community resources (e.g., financial services, programs for the visually impaired, special education).
Surveillance: Regular assessment of nutritional status and swallowing, vision, mobility and environmental adaptations, speech, and communication needs.
Genetic counseling.
Genetic counseling for fatty acid hydroxylase-associated neurodegeneration (FAHN) depends on the causative genetic mechanism: FAHN caused by transmission of one pathogenic variant from each parent is inherited in an autosomal recessive manner; FAHN caused by transmission of two pathogenic variants from one parent (as the result of uniparental disomy [UPD] for chromosome 16) is a de novo event and is unlikely to recur.
Autosomal recessive inheritance: At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If the pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic diagnosis are possible.
Diagnosis
Suggestive Findings
Fatty acid hydroxylase-associated neurodegeneration (FAHN) should be considered in individuals with the following clinical findings, neuroimaging findings, and family history (see Figure 1).
Figure 1.
Clinical findings
- Onset within the first or second decade of life
- Corticospinal tract involvement:
- Spastic paraplegia or quadriplegia (commonly given a clinical diagnosis of hereditary spastic paraplegia)
- Pyramidal tract signs (hypereflexia, clonus, Babinski sign, Hoffmann sign)
- Movement disorder including one or both of the following:
- Dystonia
- Ataxia
- Dysarthria
- Dysphagia
- Eye findings:
- Optic atrophy manifest as progressive loss of visual acuity, sectoral visual field loss, and impaired color vision
- In some individuals: strabismus, lateral-beating nystagmus, and supranuclear gaze palsy
- Epilepsy
- Cognitive decline
Neuroimaging findings. Brain MRI findings typically may include (in order of likelihood):
- On T2-weighted images: variable unilateral or bilateral symmetric white matter hyperintensity that may affect both periventricular and subcortical white matter, and may become confluent with time. U-fibers and cerebellar white matter appear to be affected to a lesser degree.
- Progressive atrophy of the cerebellar hemispheres, vermis, pons, medulla and spinal cord
- Thinning of the corpus callosum
- Optic atrophy
- T2-weighted hypointensity of the globus pallidus (may display blooming on T2*-weighted images).Note: T2-weighted hypointensity coupled with an extrapyramidal movement disorder and intellectual decline is suggestive of a neurodegeneration with brain iron accumulation (NBIA) disorder (see Differential Diagnosis). The "eye of the tiger" sign, pathognomonic for pantothenate kinase-associated neurodegeneration (PKAN), another form of NBIA, is not seen in FAHN.
Family history is consistent with autosomal recessive inheritance, including parental consanguinity.
Establishing the Diagnosis
The diagnosis of FAHN is established in a proband with suggestive findings and biallelic FA2H pathogenic variants on molecular genetic testing (see Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, multigene panel) and comprehensive genomic testing (exome sequencing, exome array, genome sequencing) depending on the phenotype.
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with findings indistinguishable from other neurodegenerative disorders with pyramidal and extrapyramidal involvement are more likely to be diagnosed with comprehensive genomic testing (see Option 2).
Option 1
When the phenotypic and imaging findings suggest the diagnosis of FAHN or a similar type of neurodegeneration with brain iron accumulation (see NBIA Overview), molecular genetic testing is most often a multigene panel.
A multigene panel that includes FA2H and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Option 2
When the phenotype is indistinguishable from many other inherited neurodegenerative disorders with pyramidal and extrapyramidal involvement, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best option. Exome sequencing is most commonly used; genome sequencing is also possible.
If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Gene 1 | Method | Proportion of Pathogenic Variants 2 Detectable by Method |
---|---|---|
FA2H | Sequence analysis 3 | >95% 4 |
Gene-targeted deletion/duplication analysis 5 | See footnote 6 | |
Uniparental disomy (UPD) analysis 7 | See footnote 8 |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Kruer et al [2010]
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 6.
One reported to date [Pierson et al 2012]
- 7.
Various methods can detect UPD in an apparent FA2H homozygote. Testing may require parental blood specimens.
- 8.
Four probands from nonconsanguineous families had uniparental disomy (UPD, maternal or paternal) [Soehn et al 2016]. For probands with apparent homozygous FA2H pathogenic variants and no evidence of large gene deletions, parental testing and/or investigation of the proband for UPD are recommended. The presence of UPD will alter recurrence risks (see Genetic Counseling).
Clinical Characteristics
Clinical Description
Fatty acid hydroxylase-associated neurodegeneration (FAHN) is characterized early in the disease course by central nervous system involvement including corticospinal tract involvement (spasticity), mixed movement disorder (ataxia/dystonia), eye findings (optic atrophy, oculomotor abnormalities), and later in the disease course by progressive intellectual impairment and seizures. FAHN is a subtype of neurodegeneration with brain iron accumulation (NBIA) but is also included under the classifications of leukodystrophies and hereditary spastic paraplegias.
Of note, leukodystrophy and hereditary spastic paraplegia 35 (HSP35), two phenotypes previously considered distinct disorders based on clinical findings [Dick et al 2008, Edvardson et al 2008], are now included in the phenotypic spectrum of FAHN based on molecular genetic findings [Dick et al 2010, Kruer et al 2010].
The most frequent presenting finding is a subtle change in gait that may lead to increasingly frequent falls. This typically occurs in childhood or adolescence and may be the result of focal dystonia and/or corticospinal tract involvement.
The degree of spasticity resulting from corticospinal tract involvement can vary among persons with FAHN. Individuals affected to a lesser degree may develop spastic paraparesis but retain the ability to walk, while individuals with more severe disease may demonstrate a spastic quadriplegic pattern of disability and lose their ability to ambulate, instead relying on a wheelchair.
Dystonia may begin focally (e.g., affecting one foot) but typically spreads to assume a generalized pattern. The degree of dystonia seen in FAHN is generally milder than that in other forms of NBIA, such as PKAN, in which status dystonicus occurs.
Ataxia typically begins in childhood or adolescence and may emerge along with dystonia and/or spasticity. The ataxia that occurs in FAHN may affect both axial and appendicular function and, along with both dystonia and spasticity, can markedly impair gait.
Dysarthria may be prominent in FAHN. In some individuals, expressive speech can be impaired to the point of anarthria. Dysphagia, potentially necessitating gastrostomy tube placement, can also occur.
Optic atrophy in FAHN may begin as a subtle loss of visual acuity in childhood, but may progress to the point of functional blindness. The oculomotor abnormalities seen in FAHN may impair functional vision as well.
A few individuals with FAHN and peripheral neuropathy have been reported [Donkervoort et al 2014, Zaki et al 2015].
Seizures are not typically seen in the early stages of disease, but may occur later in the disease course. When present, seizures (which tend to be complex partial or generalized) are typically infrequent and respond relatively well to anticonvulsants.
While progressive intellectual impairment occurs in most persons with FAHN, more information on the cognitive phenotype and natural history are needed. Serial assessments have documented cognitive decline in two individuals [Tonelli et al 2012]. One report suggests a psychiatric component to FAHN based on findings of anxiety, depression, and bipolar disorder in affected sibs [Magariello et al 2017].
Although the neurodegeneration in FAHN is progressive, declines may be intermittent and punctuated by periods of relative clinical stability. However, lost skills are not usually regained. With disease progression, dystonia and spasticity compromise the ability to ambulate, leading to wheelchair dependence.
Life expectancy. Although premature death often occurs in the 20s or 30s secondary to a combination of nutrition-related immunodeficiency and respiratory compromise, life expectancy is variable.
Neuropathologic features for FAHN have not yet been reported. Bone marrow biopsy, although not necessary for diagnosis, may demonstrate accumulation of granular histiocytes.
Genotype-Phenotype Correlations
No genotype-phenotype correlations have been observed for pathogenic variants in FA2H.
Nomenclature
Historically, the FA2H-related phenotype has been classified as either a genetic leukodystrophy [Vanderver et al 2015] or a hereditary spastic paraplegia (SPG35) (see OMIM 612319) [Dick et al 2008, Soehn et al 2016].
The authors prefer to refer to the FA2H-related phenotype as fatty acid hydroxylase-associated neurodegeneration because this term refers to the genetic basis of the disorder and encompasses all clinical classifications.
Prevalence
No reliable prevalence data are available. However, the prevalence is estimated to be lower than one in 1,000,000.
Differential Diagnosis
Fatty acid hydroxylase-associated neurodegeneration (FAHN) is a neurodegenerative disorder that shows clinical overlap with other early-onset neurodegenerative disorders. Disorders that may exhibit clinical and neuroimaging features similar to those seen in FAHN are summarized in Table 2.
Table 2.
Phenotype | Disorder | Gene(s) | MOI | Additional Clinical & MRI Features of Differential Diagnosis Disorder | |
---|---|---|---|---|---|
Overlapping w/FAHN | Distinguishing from FAHN | ||||
Other NBIA disorders | MPAN | C19orf12 | AR |
|
|
PKAN | PANK2 | AR | Progressive dystonia & dysarthria |
| |
Juvenile PLAN (atypical NAD) | PLA2G6 | AR |
|
| |
CoPAN | COASY | AR | Childhood-onset gait abnormalities w/cognitive/psychiatric features |
| |
Neurodegenerative mineral deposition disorder | Wilson disease | ATP7B | AR |
|
|
Clinical mimics w/spasticity, dystonia, ataxia, or combination | |||||
Hereditary ataxia | Friedreich ataxia | FXN | AR |
|
|
ARSACS | SACS | AR |
|
| |
PLP1 null syndrome (see PLP1-related disorders) | PLP1 | XL | Childhood-onset spasticity & ataxia | Multifocal demyelinating polyneuropathy | |
Spastic paraplegia 2 (see PLP1-related disorders) | PLP1 | XL |
|
| |
Spastic paraplegia 44 | GJC2 | AR |
|
| |
Spastic paraplegia 11 | SPG11 | AR |
| More frequent peripheral neuropathy | |
Spastic paraplegia 15 | ZFYVE26 | AR | |||
Arylsulfatase A deficiency (juvenile metachromatic leukodystrophy) | ARSA | AR |
|
| |
Hypomyelination with atrophy of the basal ganglia and cerebellum (see TUBB4A-Related Leukodystrophy) | TUBB4A | AR |
|
| |
POLR3-related leukodystrophy | POLR3A POLR3B POLR3C | AR |
|
| |
Other disorders | Juvenile & chronic hexosaminidase A deficiency | HEXA | AR |
|
|
GTP cyclohydrolase 1-deficient dopa-responsive dystonia | GCH1 | AR | Childhood-onset gait abnormalities, spasticity, & brisk reflexes |
|
AD = autosomal dominant; AR = autosomal recessive; ARSACS = autosomal recessive spastic ataxia of Charlevoix Saguenay; MOI = mode of inheritance; NBIA = neurodegeneration with brain iron accumulation; XL = X-linked
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease in an individual diagnosed with fatty acid hydroxylase-associated neurodegeneration (FAHN), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
System/Concern | Evaluation | Comment |
---|---|---|
Eyes | Ophthalmologic evaluation | To incl visual acuity & examination for optic atrophy or eye movement abnormalities |
Feeding | Multidisciplinary team evaluation | Attention to nutritional status & feeding |
Musculoskeletal | Physical & occupational therapy | Mobility & self-help skills |
Neurologic | Neurologic evaluation | For dystonia, ataxia, spasticity; incl EEG if question of seizures. |
Miscellaneous/ Other | Developmental assessment | To incl motor, general cognitive, & vocational skills |
Speech & language pathologist | Speech & communication, augmentative devices | |
Consultation w/clinical geneticist &/or genetic counselor |
Treatment of Manifestations
Eyes
Refer those with visual impairment to appropriate community resources.
Feeding
Once swallowing evaluation and nutrition assessments indicate that the individual cannot maintain adequate nutrition and/or avoid the risk of aspiration with oral feeding, gastrostomy tube placement is indicated.
Neurologic
Pharmacologic and surgical interventions are focused on palliation of symptoms.
Dystonia and spasticity can be debilitating. Symptomatic treatments used with varying success include the following:
- Oral trihexyphenidyl, baclofen, tizanidine, benzodiazepines, and/or dantrolene. Of note, while levodopa could potentially provide benefit, it often does not; thus, a trial is reasonable, but should only be continued if there is clear benefit.
- Intramuscular botulinum toxin targeting abnormal co-contraction of selected muscle groups
- Ablative pallidotomy or thalamotomy. Dystonia may return despite this aggressive measure [Justesen et al 1999].
Ataxia. Therapies for cerebellar ataxia can include use of weighted gloves to assist with dysmetria. Note that riluzole, recently recommended for cerebellar ataxia [Ristori et al 2010], has not to the authors' knowledge undergone a therapeutic trial in FAHN.
Seizures. Seizures respond well to traditional management with antiepileptic drugs.
Education of parents regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for parents or caregivers of children diagnosed with epilepsy, see Epilepsy & My Child Toolkit.
Motor Dysfunction
Gross motor dysfunction
- Physical therapy is recommended to maximize mobility.
- Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).
Communication issues. Consider evaluation for alternative means of communication (e.g., Augmentative and Alternative Communication [AAC]) for individuals who have expressive language difficulties.